Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt (2017 - 2025)

Historic Total Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q3 2025 value amounting to $312.9 million.

  • Ani Pharmaceuticals' Total Debt fell 223.45% to $312.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.9 million, marking a year-over-year decrease of 223.45%. This contributed to the annual value of $318.3 million for FY2024, which is 713.43% up from last year.
  • Ani Pharmaceuticals' Total Debt amounted to $312.9 million in Q3 2025, which was down 223.45% from $314.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Total Debt high stood at $320.1 million for Q3 2024, and its period low was $183.4 million during Q1 2021.
  • Moreover, its 5-year median value for Total Debt was $287.4 million (2021), whereas its average is $284.3 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Total Debt tumbled by 827.29% in 2021 and then skyrocketed by 5655.45% in 2022.
  • Ani Pharmaceuticals' Total Debt (Quarter) stood at $287.4 million in 2021, then dropped by 0.3% to $286.5 million in 2022, then increased by 3.69% to $297.1 million in 2023, then increased by 7.13% to $318.3 million in 2024, then fell by 1.68% to $312.9 million in 2025.
  • Its Total Debt was $312.9 million in Q3 2025, compared to $314.7 million in Q2 2025 and $316.5 million in Q1 2025.